» Articles » PMID: 35223870

Exosomes Immunity Strategy: A Novel Approach for Ameliorating Intervertebral Disc Degeneration

Overview
Specialty Cell Biology
Date 2022 Feb 28
PMID 35223870
Authors
Affiliations
Soon will be listed here.
Abstract

Low back pain (LBP), which is one of the most severe medical and social problems globally, has affected nearly 80% of the population worldwide, and intervertebral disc degeneration (IDD) is a common musculoskeletal disorder that happens to be the primary trigger of LBP. The pathology of IDD is based on the impaired homeostasis of catabolism and anabolism in the extracellular matrix (ECM), uncontrolled activation of immunologic cascades, dysfunction, and loss of nucleus pulposus (NP) cells in addition to dynamic cellular and biochemical alterations in the microenvironment of intervertebral disc (IVD). Currently, the main therapeutic approach regarding IDD is surgical intervention, but it could not considerably cure IDD. Exosomes, extracellular vesicles with a diameter of 30-150 nm, are secreted by various kinds of cell types like stem cells, tumor cells, immune cells, and endothelial cells; the lipid bilayer of the exosomes protects them from ribonuclease degradation and helps improve their biological efficiency in recipient cells. Increasing lines of evidence have reported the promising applications of exosomes in immunological diseases, and regarded exosomes as a potential therapeutic source for IDD. This review focuses on clarifying novel therapies based on exosomes derived from different cell sources and the essential roles of exosomes in regulating IDD, especially the immunologic strategy.

Citing Articles

Innovating intervertebral disc degeneration therapy: Harnessing the power of extracellular vesicles.

Chen S, Dou Y, Zhang Y, Sun X, Liu X, Yang Q J Orthop Translat. 2025; 50:44-55.

PMID: 39868351 PMC: 11761297. DOI: 10.1016/j.jot.2024.09.014.


Bioinformatic analysis and identification of macrophage polarization-related genes in intervertebral disc degeneration.

Liu L, Peng S, Shi B, Yu G, Liang Y, Zhang Y Am J Transl Res. 2024; 16(5):1891-1906.

PMID: 38883390 PMC: 11170579. DOI: 10.62347/HBDY5086.


Bioinformatics-based discovery of intervertebral disc degeneration biomarkers and immune-inflammatory infiltrates.

Song C, Zhou D, Cheng K, Liu F, Cai W, Mei Y JOR Spine. 2024; 7(1):e1311.

PMID: 38222811 PMC: 10782055. DOI: 10.1002/jsp2.1311.


Current status and development direction of immunomodulatory therapy for intervertebral disk degeneration.

Gao Y, Chen X, Zheng G, Lin M, Zhou H, Zhang X Front Med (Lausanne). 2024; 10:1289642.

PMID: 38179277 PMC: 10764593. DOI: 10.3389/fmed.2023.1289642.


Multifunctional injectable hydrogels with controlled delivery of bioactive factors for efficient repair of intervertebral disc degeneration.

Han H, Zhao X, Ma H, Zhang Y, Lei B Heliyon. 2023; 9(11):e21867.

PMID: 38027562 PMC: 10665751. DOI: 10.1016/j.heliyon.2023.e21867.


References
1.
Wang Z, Wu Y, Zhao Z, Liu C, Zhang L . Study on Transorgan Regulation of Intervertebral Disc and Extra-Skeletal Organs Through Exosomes Derived From Bone Marrow Mesenchymal Stem Cells. Front Cell Dev Biol. 2021; 9:741183. PMC: 8495158. DOI: 10.3389/fcell.2021.741183. View

2.
Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

3.
Forsberg M, Kink J, Hematti P, Capitini C . Mesenchymal Stromal Cells and Exosomes: Progress and Challenges. Front Cell Dev Biol. 2020; 8:665. PMC: 7379234. DOI: 10.3389/fcell.2020.00665. View

4.
Sambrook P, MacGregor A, Spector T . Genetic influences on cervical and lumbar disc degeneration: a magnetic resonance imaging study in twins. Arthritis Rheum. 1999; 42(2):366-72. DOI: 10.1002/1529-0131(199902)42:2<366::AID-ANR20>3.0.CO;2-6. View

5.
Munich S, Sobo-Vujanovic A, Buchser W, Beer-Stolz D, Vujanovic N . Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology. 2012; 1(7):1074-1083. PMC: 3494621. DOI: 10.4161/onci.20897. View